drugset / Trial / NCT02644863
Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer
Phase 2
Unknown
60 enrolled
Shenzhen Hornetcorn Bio-technology Company, LTD
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the safety and efficacy of D-CIK immune cells combined with chemotherapy after resection of esophageal cancer
Timeline
- Start
- 2015-12
- Primary completion
- 2018-12
- Completion
- 2019-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC-CIK | Cell therapy | 8e+09 cells | Intravenous |
| Background | Cisplatin | Other / unclassified | 30 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |